About Complement factor H-related protein 3
Complement factor H-related protein 3 (CFHR3) is a protein
from Homo sapiens identified by UniProt accession
Q02985, 330 residues long.
MolForge cross-references it against 0 known binders and
108 disease associations.
Target properties
| Protein name | Complement factor H-related protein 3 |
| UniProt accession | Q02985 |
| Gene | CFHR3 |
| Organism | Homo sapiens |
| Length | 330 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (108)
Diseases linked to this target (Open Targets).
- age-related macular degeneration · score 0.46
- atypical hemolytic-uremic syndrome · score 0.39
- blood protein measurement · score 0.34
- atypical hemolytic-uremic syndrome with I factor anomaly · score 0.34
- total blood protein measurement · score 0.26
- complement component C8 measurement · score 0.24
- complement factor H measurement · score 0.23
- complement factor H-related protein 1 measurement · score 0.22
- IGA glomerulonephritis · score 0.22
- coagulation factor measurement · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q02985-F1 | alphafold | PREDICTED | 91.74 | — |
Amino-acid sequence (330 residues)
MLLLINVILT LWVSCANGQV KPCDFPDIKH GGLFHENMRR PYFPVAVGKY YSYYCDEHFE TPSGSYWDYI HCTQNGWSPA VPCLRKCYFP YLENGYNQNY GRKFVQGNST EVACHPGYGL PKAQTTVTCT EKGWSPTPRC IRVRTCSKSD IEIENGFISE SSSIYILNKE IQYKCKPGYA TADGNSSGSI TCLQNGWSAQ PICINSSEKC GPPPPISNGD TTSFLLKVYV PQSRVEYQCQ PYYELQGSNY VTCSNGEWSE PPRCIHPCII TEENMNKNNI KLKGRSDRKY YAKTGDTIEF MCKLGYNANT SILSFQAVCR EGIVEYPRCE
Explore Complement factor H-related protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets